Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: Is the slope of the curve the shape of the future?

JAMA

Volumn 293, Issue 8, 2005, Pages 979-986

  Gersh, Bernard J ^a   Stone, Gregg W ^b   White, Harvey D ^c   Holmes, David R ^a  

^a MAYO CLINIC   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; TENECTEPLASE;

ACUTE HEART INFARCTION; ANGIOGRAPHY; ARTERY; CLINICAL TRIAL; DRUG EFFICACY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HUMAN; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; VASCULAR PATENCY; HEART INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 13944271065     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.8.979     Document Type: Review

References (80)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
2. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. JAMA. 1993;270:1211-1216.
3. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction. Am J Cardiol. 2003;92:824-826.
4. Angeja BG, Gibson CM, Chin R, et al; National Registry of Myocardial Infarction 2-3. Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol. 2002;89:1156-1161.
5. Giugliano RP, Braunwald E. Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it's all a matter of time. Circulation. 2003;108:2828-2830.
6. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage: results of clinical trials and the animal paradigm-paradoxic or predictable? Circulation. 1993;88:296-306.
7. Singh M, Ting HH, Berger PB, Garratt KN, Holmes DR Jr, Gersh BJ. Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal. J Am Coll Cardiol. 2002;39:1881-1889.
8. Singh M, Ting HH, Gersh BJ, et al. Percutaneous coronary intervention for ST-segment and non-ST-segment elevation myocardial infarction at hospitals with and without on-site cardiac surgical capability. Mayo Clin Proc. 2004;79:738-744.
9. Wennberg DE, Lucas FL, Siewers AE, et al. Outcomes of percutaneous coronary interventions performed at centers without and with onsite coronary artery bypass graft surgery. JAMA. 2004;292:1961-1968.
10. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death, II: transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979;40:633-644.
11. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction. Lancet. 1996;348:771-775.
12. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation. 1989;79:441-444.
13. Califf RM, Topol EJ, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction. J Am Coll Cardiol. 1989;14:1382-1388.
14. Sadanandan S, Buller C, Menon V, et al. The late open artery hypothesis-a decade later. Am Heart J. 2001;142:411-421.
15. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588.
16. Roe MT, Ohman EM, Maas AC, et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol. 2001;37:9-18.
17. Steg PG, Thuaire C, Himbert D, et al; DECOPI Investigators. DECOPI (Desobstruction Coronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J. 2004;25:2187-2194.
18. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125-130.
19. Mathew V, Gersh BJ. To open or not to open: that remains the question. Eur Heart J. 2004;25:2177-2179.
20. Bax M, de Winter RJ, Schotborgh CE, et al. Short- and long-term recovery of left ventricular function predicted at the time of primary percutaneous coronary intervention in anterior myocardial infarction. J Am Coll Cardiol. 2004;43:534-541.
21. Prasad A, Stone GW, Aymong E, et al. Impact of ST-segment resolution following primary angioplasty on outcomes after myocardial infarction in elderly patients. Am Heart J. 2004;147:669-675.
22. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941-2947.
23. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patientswith acute myocardial infarction. Circulation. 1999;100:14-20.
24. Brodie BR, Cox DA, Stuckey TD, et al. How important is time to treatment with primary percutaneous coronary intervention for acute myocardial infarction? results from the CADILLAC trial [abstract]. J Am Coll Cardiol. 2003;41(suppl A):368A.
25. Antoniucci D, Valenti R, Migliorini A, et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2002;89:1248-1252.
26. De Luca G, Suryapranata H, Zijlstra F, et al; ZWOLLE Myocardial Infarction Study Group. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2003;42:991-997.
27. Brodie BR, Stone GW, Morice M-C, et al; Stent Primary Angioplasty in Myocardial Infarction Study Group. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2001;88:1085-1090.
28. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108:1809-1814.
29. Waters RE II, Singh KP, Roe MT, et al. Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;43:2153-2159.
30. Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol. 2000;85:13-18.
31. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction. Circulation. 2001;104:636-641.
32. De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2004;43:1363-1367.
33. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Circulation. 2004;109:1223-1225.
34. Ross AM, Coyne KS, Reiner JS, et al; PACT Investigators. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol. 1999;34:1954-1962.
35. Rogers WJ, Baim DS, Gore JM, et al; TIMI II-A Investigators. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Circulation. 1990;81:1457-1476.
36. Simoons ML, Arnold AER, Betriu A, et al; European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator (rTPA). Thrombolysis with tissue plasminogen activator in acute myocardial infarction. Lancet. 1988;1:197-203.
37. SWIFT Trial Study Group. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ. 1991;302:555-560.
38. Barbash GI, Roth A, Hod H, et al. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:538-545.
39. LeMay M. Combined Angioplasty and Pharmacological Intervention versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI trial). Paper presented at: Annual Scientific Sessions of the American College of Cardiology; March 7,2004; New Orleans, La.
40. Scheller B, Hennen B, Hammer B, et al; SIAM III Study Group. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 2003;42:634-641.
41. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al; GRACIA Group. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet. 2004;364:1045-1053.
42. O'Neill WW. "Watchful waiting" after thrombolysis. J Am Coll Cardiol. 2003;42:17-19.
43. Schweiger MJ, Cannon CP, Murphy SA, et al; TIMI 10B and TIMI 14 Investigators. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001;88:831-836.
44. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) trial. J Am Coll Cardiol. 2000;36:1489-1496.
45. Kastrati A, Mehilli J, Schlotterbeck K, et al; Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA. 2004;291:947-954.
46. Van't Hof A. ON-TIME: Ongoing Tirofiban in Myocardial Infarction Evaluation. Paper presented at: Annual Scientific Sessions of the American College of Cardiology; March 30-April 2, 2003; Chicago, Ill.
47. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation. 1992;86:1710-1717.
48. Widimský P, Groch L, Zelízko M, Aschermann M, Bednár F, Suryapranata H; PRAGUE Study Group Investigators. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. Eur Heart J. 2000;21:823-831.
49. Vermeer F, Oude Ophuis AJ, van den Berg FJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PICA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart. 1999;82:426-431.
50. Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003;42:1-6.
51. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al; GRACIA-2 Investigators. Primary optimal PCI versus facilitated intervention (tenecteplase plus stenting) in patients with ST-elevated acute myocardial infarction: the GRACIA-2 randomised trial [abstract]. Circulation. 2003;108(suppl):IV468.
52. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 2003;42:1886-1889.
53. Stone GW, Grines CL, Cox DA, et al; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.
54. Moliterno DJ, Chan AW. Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. J Am Coll Cardiol. 2003;41(suppl S): 49S-54S.
55. Halkin A, Grines CL, Cox DA, et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol. 2004;43:1780-1787.
56. Magid DJ, Calonge BN, Rumsfeld JS, et al; National Registry of Myocardial Infarction 2 and 3 Investigators. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA. 2000;284:3131-3138.
57. Taher T, Fu Y, Wagner GS, et al. Aborted myocardial infarction in patients with ST-segment elevation. J Am Coll Cardiol. 2004;44:38-43.
58. Steg PG, Bonnefoy E, Chabaud S, et al; Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) Investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty. Circulation. 2003;108:2851-2856.
59. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
60. Widimský P, Buděšínský T, Voráč D, et al; 'PRAGUE' Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Eur Heart J. 2003;24:94-104.
61. Welsh RC, Ornato J, Armstrong PW. Prehospital management of acute ST-elevation myocardial infarction. Am Heart J. 2003;145:1-8.
62. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999. J Am Coll Cardiol. 2000;36:2056-2063.
63. Canto JG, Zalenski RJ, Ornato JP, et al; National Registry of Myocardial Infarction 2 Investigators. Use of emergency medical services in acute myocardial infarction and subsequent quality of care. Circulation. 2002;106:3018-3023.
64. Schomig A, Ndrepepa G, Mehilli J, et al. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation. 2003;108:1084-1088.
65. Zeymer U, Tebbe U, Essen R, et al; ALKK-Study Group. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. Am Heart J. 1999;137:34-38.
66. Becker RC, Charlesworth A, Wilcox RG, et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study. J Am Coll Cardiol. 1995;25:1063-1068.
67. Honan MB, Harrell FE Jr, Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol. 1990;16:359-367.
68. Lew AS, Laramee P, Cercek B, et al. The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction. Circulation. 1985;72:1053-1058.
69. Van de Werf F, Barron HV, Armstrong PW, et al; ASSENT-2 Investigators. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001;22:2253-2261.
70. Tcheng JE, Kandzari DE, Grines CL, et al; CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction. Circulation. 2003;108:1316-1323.
71. White HD. Thrombolytic therapy in the elderly. Lancet. 2000;356:2028-2030.
72. French JK, Feldman HA, Assmann SF, et al. Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J. 2003;146:804-810.
73. Berger PB, Ryan TJ. Inferior myocardial infarction: high-risk subgroups. Circulation. 1990;81:401-411.
74. Schomig A, Ndrepepa G, Mehilli J, et al; STOPAMI-4 Study Investigators. A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol. 2004;44:2073-2079.
75. Sutton AG, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44:287-296.
76. Verheugt FW. Lyse now, stent later: the grace of GRACIA. Lancet. 2004;364:1014-1015.
77. Grech ED, Sutton AG, Campbell PG, et al. Reappraising the role of immediate intervention following thrombolytic recanalization in acute myocardial infarction. Am J Cardiol. 2000;86:400-405.
78. Canto JG, Rogers WJ, Zhang Y, et al; National Registry of Myocardial Infarction 2 Investigators. The association between the on-site availability of cardiac procedures and the utilization of those services for acute myocardial infarction by payer group. Clin Cardiol. 1999;22:519-524.
79. Ellis SG, Armstrong P, Betriu A, et al; FINESSE Investigators. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention. Am Heart J. 2004;147:e16.
80. Eagle KA, Goodman SG, Avezum Á, Budaj A, Sullivan CM, López-Sendón J; GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction. Lancet. 2002;359:373-377.